Mind Medicine (MindMed) Inc at ROTH Conference Transcript
And with me now is the CEO of MindMed, Rob Barrow. Welcome, Rob. Nice to have you.
Questions & Answers
So regarding the relatively potent hallucinogens as potential commercial drugs, can you describe the regulatory environment both here and in Europe for a fairly new class of drugs that can take people in different directions?
()-&
Absolutely. Thanks so much for having us here in the conference. So for anyone who is not deeply acquainted with Mind Medicine, we're developing a portfolio of molecules for a variety of brain health disorders, the furthest along of which is a proprietary form of LSD, which we're developing for generalized anxiety disorder, Phase 2b study this year.
We're also developing other models by using these molecules, including a sub-perceptual,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |